In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod
With a second positive phase 3 trial in hand, Sanofi and Regeneron have said they plan to file for approval of Dupixent in chronic obstructive pulmonary disease (COPD), a
A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the
A comprehensive digital approach to helping patients manage type 2 diabetes, combining continuous glucose monitoring (CGM) devices, wearables and a mobile app, has been sh
Sosei Heptares has lost GSK as a partner for an inflammatory bowel disease (IBD) drug candidate GSK4381406, but says it will take the programme forward as it has significa